By Adriano Marchese Amylyx Pharmaceuticals said Friday that it received an initial negative opinion from an EU regulator on the marketing authorization.
Amylyx Pharmaceuticals Inc. shares fell 7.5% premarket on Friday after the company said the European Medicines Agency had confirmed its negative opinion on.
Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Get Free Report) saw unusually-strong trading volume on Monday . Approximately 2,463,247 shares changed hands during mid-day trading, an increase of 142% from the previous session’s volume of 1,017,837 shares.The stock last traded at $18.32 and had previously closed at $18.48. Analyst Ratings Changes Several equities analysts have […]
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Get Free Report) shares were down 5.3% on Monday . The stock traded as low as $18.56 and last traded at $18.73. Approximately 539,785 shares were traded during mid-day trading, a decline of 47% from the average daily volume of 1,013,052 shares. The stock had previously closed at $19.78. Analyst […]
Altium Capital Management LP lifted its holdings in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Free Report) by 32.1% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 185,000 shares of the company’s stock after purchasing an additional 45,000 […]